Corcept Therapeutics Stock Falls 50% as EPS Forecast Hits $0.33 on $254.9M Revenue
Corcept Therapeutics is expected to report fourth-quarter EPS of $0.33 on revenue of $254.9 million on February 24, 2026, while P/E ratio stands at 36.73 and current ratio at 3.14. The stock has plunged 50% after a securities class action claims the company ignored FDA warnings on its lead therapy relacorilant.
1. Upcoming Q4 Earnings and Financial Health
Corcept Therapeutics is scheduled to announce fourth-quarter 2025 earnings on February 24, 2026 after market close, with analysts forecasting EPS of $0.33 and revenue of $254.9 million. Valuation remains elevated with a P/E ratio of 36.73, price-to-sales of 5.29 and debt-to-equity of 0.01, while a current ratio of 3.14 signals solid liquidity.
2. Securities Lawsuit Triggers Sharp Stock Decline
A securities class action lawsuit filed by Allegheny County Employees’ Retirement System alleges the company ignored FDA warnings about its lead drug relacorilant, triggering a 50% stock price decline. Investors are monitoring the suit’s impact on product approvals and revenue potential as the deadline for lead plaintiff applications approaches on April 21.